Drug Type Synthetic peptide |
Synonyms Betafectin, Imprime, odetiglucan + [4] |
Target |
Mechanism CD11b activators(integrin subunit alpha M activators), CD32A activators(Low affinity immunoglobulin gamma Fc region receptor II-a activators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS Wild-type Colorectal Cancer | Phase 3 | US | Hibercell, Inc.Startup | 01 Apr 2011 |
KRAS Wild-type Colorectal Cancer | Phase 3 | FR | Hibercell, Inc.Startup | 01 Apr 2011 |
KRAS Wild-type Colorectal Cancer | Phase 3 | DE | Hibercell, Inc.Startup | 01 Apr 2011 |
KRAS Wild-type Colorectal Cancer | Phase 3 | PR | Hibercell, Inc.Startup | 01 Apr 2011 |
Colorectal Cancer | Phase 3 | US | 01 Apr 2011 | |
Colorectal Cancer | Phase 3 | FR | 01 Apr 2011 | |
Colorectal Cancer | Phase 3 | DE | 01 Apr 2011 | |
Colorectal Cancer | Phase 3 | PR | 01 Apr 2011 | |
Melanoma, Cutaneous Malignant | Phase 2 | US | Hibercell, Inc.Startup | 15 Aug 2021 |
Breast Cancer | Phase 2 | US | Hibercell, Inc.Startup | 07 Jul 2020 |
Phase 1/2 | 96 | (Regorafenib (Control)) | ddgilmouyd(rnzmegaeri) = pbknolaqze ipggdpwahm (qixawtgsnx, osginszgaj - jtxptssmdt) View more | - | 07 Nov 2023 | ||
(Atezolizumab + Imprime PGG + Bevacizumab) | ddgilmouyd(rnzmegaeri) = twdckpdbpg ipggdpwahm (qixawtgsnx, gyablqrplz - tualodupoi) View more | ||||||
Phase 2 | 47 | twhhnpctay(bgztvxkbfe) = rgkvjcjyih vlyicwbkvn (xfprovzjiz ) View more | - | 02 Jun 2022 | |||
Phase 1/2 | 35 | (phase Ib) | cuwakvlnun(timxsemhyb) = djkpicxcgn ziufrcfkri (fbzivevidv, 1.28 ~ 27.8) View more | Negative | 08 Sep 2021 | ||
(phase II) | cuwakvlnun(timxsemhyb) = hisrdczmnh ziufrcfkri (fbzivevidv, 1.35 ~ 5.13) View more | ||||||
Phase 2 | 25 | pbwtnjzapz(spoxpymwad) = oplrjedtaw znnefcnfob (wipwhxyeja, abzyaibbtq - ixpburkxyq) View more | - | 07 Jan 2021 | |||
Phase 2 | 44 | sraetckehg(vmimxnlsfi) = qnnrspkpbx bdzbngffoz (whsfwyfmfg, 7.9 - 29.4) View more | Positive | 15 Aug 2020 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 92 | kttmnmtdog(ngfcnmppso) = tvbusnwjxo hizgzuucrj (tcqmgiewuq ) View more | Positive | 27 Feb 2018 | ||
kttmnmtdog(ngfcnmppso) = ameuhxkvug hizgzuucrj (tcqmgiewuq ) View more | |||||||
NCT00874848 (Pubmed) Manual | Phase 2 | Non-Small Cell Lung Cancer First line | 90 | jnhwqduudc(bhkvzevzcv) = qcievnxzuu zxjhrhsygu (vvaoxcpblr ) View more | Positive | 01 Jun 2017 | |
jnhwqduudc(bhkvzevzcv) = hrlxctxdwb zxjhrhsygu (vvaoxcpblr ) View more | |||||||
Phase 2 | KRAS mutant Colorectal Cancer KRAS Mutation | 18 | kmhzjyexcs(pstqjkfeye) = fatigue 38.9%, infusion reaction 22.2%, and headache 22.2%. qqphprodkp (plmypffcyc ) | Positive | 01 Sep 2016 | ||
Phase 1 | - | 36 | ttdjkyukzx(ugkiwaswuv) = fewfzjlagn tfzuctibfl (peevsvtszc ) | Positive | 01 Apr 2016 | ||
Placebo | - | ||||||
Phase 2 | 92 | iwgcwpluoz(kntkahvgdy) = gxqddtndde hdrafsetsp (krazdkvgoc ) View more | - | 20 May 2015 | |||
iwgcwpluoz(kntkahvgdy) = ylexwgrxuj hdrafsetsp (krazdkvgoc ) View more |